New! View global litigation for patent families

WO1992017211A1 - Inhibition d'un retrovirus a l'aide d'acides nucleiques non codants s'hybridant sur des sequences d'encapsidation - Google Patents

Inhibition d'un retrovirus a l'aide d'acides nucleiques non codants s'hybridant sur des sequences d'encapsidation

Info

Publication number
WO1992017211A1
WO1992017211A1 PCT/US1992/002911 US9202911W WO1992017211A1 WO 1992017211 A1 WO1992017211 A1 WO 1992017211A1 US 9202911 W US9202911 W US 9202911W WO 1992017211 A1 WO1992017211 A1 WO 1992017211A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
rna
antisense
virus
dna
sequence
Prior art date
Application number
PCT/US1992/002911
Other languages
English (en)
Inventor
Thomas E. Wagner
Lei Han
Original Assignee
Edison Animal Biotechnology Center, Ohio University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

Cette invention concerne des molécules d'acide nucléique non codantes qui ne s'hybrident pratiquement que sur la séquence d'encapsidation d'un retrovirus et qui inhibent par conséquent l'encapsidation de l'ARN du génome du rétrovirus. Les molecules non codantes peuvent être de l'ADN, de l'ARN, ou des analogues de ces derniers. On peut administrer les molécules non codantes sous forme médicamenteuse ou bien l'individu devant être protégé peut être soumis à des manipulations génétiques afin d'exprimer un ARN non codant.
PCT/US1992/002911 1991-04-05 1992-04-03 Inhibition d'un retrovirus a l'aide d'acides nucleiques non codants s'hybridant sur des sequences d'encapsidation WO1992017211A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US68087391 true 1991-04-05 1991-04-05
US680,873 1991-04-05

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP51004892A JPH06506599A (fr) 1991-04-05 1992-04-03

Publications (1)

Publication Number Publication Date
WO1992017211A1 true true WO1992017211A1 (fr) 1992-10-15

Family

ID=24732881

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/002911 WO1992017211A1 (fr) 1991-04-05 1992-04-03 Inhibition d'un retrovirus a l'aide d'acides nucleiques non codants s'hybridant sur des sequences d'encapsidation

Country Status (4)

Country Link
EP (1) EP0578776A4 (fr)
JP (1) JPH06506599A (fr)
CA (1) CA2107789A1 (fr)
WO (1) WO1992017211A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4225094A1 (de) * 1992-04-28 1993-11-04 Frank Andreas Harald Meyer Medikament zur gentherapeutischen behandlung von menschen, tieren und pflanzen, insbesondere zur blockierung der virenvermehrung und der tumorgene sowie verfahren zur herstellung des medikaments
EP0594881A1 (fr) * 1991-08-10 1994-05-04 Bayer Ag Vecteurs d'expression et leur utilisation pour la production de cellules humaines résistantes au HIV pour les applications thérapeutiques
EP0598935A1 (fr) * 1992-11-24 1994-06-01 Bayer Ag Vecteurs d'expression et leur utilisation pour la production de cellules humaines résistantes à HIV pour utilisation thérapeutique
FR2702152A1 (fr) * 1993-03-03 1994-09-09 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.
WO1995018854A1 (fr) * 1994-01-05 1995-07-13 Gene Shears Pty., Ltd. Ribozymes ciblant les produits de recombinaison d'expression de sequences d'encapsidation retrovirales et retrovirus recombines contenant lesdits produits de recombinaison
WO1995027783A1 (fr) * 1994-04-06 1995-10-19 Joshi Sukhwal Sadna Inhibition de la multiplication du vih-1 dans des cellules de mammiferes
WO1996022368A1 (fr) * 1995-01-18 1996-07-25 Gene Shears Pty. Ltd. Ribozymes de recombinaison cibles contre des sequences exprimant la capside retrovirale et retrovirus contenant de tels produits recombines
US5583035A (en) * 1992-12-07 1996-12-10 Bayer Aktiengesellschaft HIV antisense expression vectors
US5712384A (en) * 1994-01-05 1998-01-27 Gene Shears Pty Ltd. Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US6458529B1 (en) 1992-09-25 2002-10-01 Aventis Pharma S.A. Assays for promoter operability in central nervous system cells
US7345025B2 (en) 2001-07-10 2008-03-18 Johnson & Johnson Research Pty. Limited Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
US7994144B2 (en) 2001-07-10 2011-08-09 Johnson & Johnson Research Pty, Limited Process for the preparation of a composition of genetically modified hematopoietic progenitor cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757055A (en) * 1980-11-12 1988-07-12 The Johns Hopkins University Method for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740463A (en) * 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
DE3853139T2 (de) * 1987-06-26 1995-06-14 Syntro Corp Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung.
DE68929343T2 (de) * 1988-02-16 2002-09-12 Greatbatch Gen Aid Ltd Modifizierte Zellen mit Resistenz gegen Retroviralinfektionen
DE68925278T2 (de) * 1988-02-26 1996-09-19 Worcester Found Ex Biology Hemmung von htlv-iii durch exogene oligonukleotide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757055A (en) * 1980-11-12 1988-07-12 The Johns Hopkins University Method for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Journal of Virology, Volume 61, No. 5, issued May 1987, BENDER et al., "Evidence that the Packaging Signal of Moloney Murine Leukemia Virus Extends into the gag Region", pages 1639-1646, see the entire document. *
Journal of Virology, Volume 61, No. 9, issued September 1987, EMBRETSON et al., "Lack of Competition Results in Efficient Packaging of Heterologous Murine Retroviral RNAs and Reticuloendotheliosis Virus Encapsidation-Minus RNAs by the Reticuloendotheliosis Virus Helper Cell Line", pages 2675-2683, see the entire *
Journal of Virology, Volume 63, No. 2, issued February 1989, VON RUDEN et al., "Inhibition of Human T-Cell Leukemia Virus Type I Replication in Primary Human T Cells that Express Antisense RNA", pages 677-682, see the entire document. *
Journal of Virology, Volume 63, No. 9, issued September 1989, LEVER et al., "Identification of a Sequence Required for Efficient Packaging of Human Immunodeficiency Virus Type 1 RNA into Virions", pages 4085-4087, see the entire document. *
Proc. Natl. Acad. Sci. USA, Volume 84, issued August 1987, LEDLEY et al., "Retroviral gene transfer into primary hepatocytes: Implications for genetic therapy of liver-specific functions", pages 5335-5339, see the entire document. *
Proc. Natl. Acad. Sci. USA, Volume 85, issued August 1988, GOODSCHILD et al., "Inhibition of Human Immunodeficiency Virus replication by antisense oligodeoxynucleotides", pages 5507-5511, see the entire document. *
Science, Volume 240, issued 10 June 1988, JAENISCH, "Transgenic Animals", pages 1468-1474, see the entire document. *
See also references of EP0578776A4 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0594881A1 (fr) * 1991-08-10 1994-05-04 Bayer Ag Vecteurs d'expression et leur utilisation pour la production de cellules humaines résistantes au HIV pour les applications thérapeutiques
DE4225094A1 (de) * 1992-04-28 1993-11-04 Frank Andreas Harald Meyer Medikament zur gentherapeutischen behandlung von menschen, tieren und pflanzen, insbesondere zur blockierung der virenvermehrung und der tumorgene sowie verfahren zur herstellung des medikaments
US6458529B1 (en) 1992-09-25 2002-10-01 Aventis Pharma S.A. Assays for promoter operability in central nervous system cells
EP0598935A1 (fr) * 1992-11-24 1994-06-01 Bayer Ag Vecteurs d'expression et leur utilisation pour la production de cellules humaines résistantes à HIV pour utilisation thérapeutique
US5583035A (en) * 1992-12-07 1996-12-10 Bayer Aktiengesellschaft HIV antisense expression vectors
FR2702152A1 (fr) * 1993-03-03 1994-09-09 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.
WO1994020146A1 (fr) * 1993-03-03 1994-09-15 Rhone-Poulenc Rorer S.A. Adenovirus recombinants et leur utilisation en therapie genique pour le traitement des pathologies oculaires
WO1995018854A1 (fr) * 1994-01-05 1995-07-13 Gene Shears Pty., Ltd. Ribozymes ciblant les produits de recombinaison d'expression de sequences d'encapsidation retrovirales et retrovirus recombines contenant lesdits produits de recombinaison
US5712384A (en) * 1994-01-05 1998-01-27 Gene Shears Pty Ltd. Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US6114167A (en) * 1994-01-05 2000-09-05 Gene Shears Pty., Ltd. Ribozymes targeting the MoMLV PSI packaging sequence and the HIV tat sequence
WO1995027783A1 (fr) * 1994-04-06 1995-10-19 Joshi Sukhwal Sadna Inhibition de la multiplication du vih-1 dans des cellules de mammiferes
WO1996022368A1 (fr) * 1995-01-18 1996-07-25 Gene Shears Pty. Ltd. Ribozymes de recombinaison cibles contre des sequences exprimant la capside retrovirale et retrovirus contenant de tels produits recombines
US7345025B2 (en) 2001-07-10 2008-03-18 Johnson & Johnson Research Pty. Limited Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
US7776595B2 (en) 2001-07-10 2010-08-17 Johnson & Johnson Research Pty, Limited Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
US7994144B2 (en) 2001-07-10 2011-08-09 Johnson & Johnson Research Pty, Limited Process for the preparation of a composition of genetically modified hematopoietic progenitor cells

Also Published As

Publication number Publication date Type
CA2107789A1 (fr) 1992-10-06 application
EP0578776A1 (fr) 1994-01-19 application
EP0578776A4 (fr) 1995-04-12 application
JPH06506599A (fr) 1994-07-28 application

Similar Documents

Publication Publication Date Title
Yu et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells
Chen et al. Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry.
Bowes et al. Localization of a retroviral element within the rd gene coding for the beta subunit of cGMP phosphodiesterase
US6107478A (en) Retroviral vector, a replication system for said vector and avian or mammalian cells transfected with said vector
Young et al. Isolation of a chicken gene that confers susceptibility to infection by subgroup A avian leukosis and sarcoma viruses.
US5741486A (en) Safe vectors for gene therapy
Stewart et al. Expression of retroviral vectors in transgenic mice obtained by embryo infection.
Wanisch et al. Integration-deficient lentiviral vectors: a slow coming of age
Hoeben et al. Inactivation of the Moloney murine leukemia virus long terminal repeat in murine fibroblast cell lines is associated with methylation and dependent on its chromosomal position.
US6743967B2 (en) Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6682907B1 (en) Use of triplex structure DNA in transferring nucleotide sequences
US5712384A (en) Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
Mariani et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif
US7303910B2 (en) Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site
US20030203868A1 (en) Inhibition of pathogen replication by RNA interference
US6395549B1 (en) Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors
US5354674A (en) Method of gene transfer using retrotransposons
Stocking et al. Endogenous retroviruses
Sullenger et al. Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication.
Hwang et al. Expression of genes introduced into cells by retroviral infection is more efficient than that of genes introduced into cells by DNA transfection.
US5837510A (en) Methods and polynucleotide constructs for treating host cells for infection or hyperproliferative disorders
Jähner et al. Insertion of the bacterial gpt gene into the germ line of mice by retroviral infection
Guild et al. Development of retrovirus vectors useful for expressing genes in cultured murine embryonal cells and hematopoietic cells in vivo.
US5716826A (en) Recombinant retroviruses
US6825396B2 (en) Methods for tissue specific synthesis of protein in eggs of transgenic hens

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1992910993

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2107789

Country of ref document: CA

ENP Entry into the national phase in:

Ref country code: CA

Ref document number: 2107789

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1992910993

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992910993

Country of ref document: EP